Predictors of Nonuse of a High-Potency Statin After an Acute
Coronary Syndrome: Insights From the Stabilization of Plaques
Using Darapladib-Thrombolysis in Myocardial Infarction 52
(SOLID-TIMI 52) Trial

J 2017

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial

EISEN, A., C.P. CANNON, E. BRAUNWALD, D.L. STEEN, J. ZHOU et. al.

Basic information

Original name

Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial

Authors

EISEN, A., C.P. CANNON, E. BRAUNWALD, D.L. STEEN, J. ZHOU, E.L. GOODRICH, K. IM, A.J. DALBY, Jindřich ŠPINAR, S. DAGA, M.A. LUKAS and M.L. O´DONOGHUE

Edition

Journal of the American Heart Association, Hoboken, Wiley-Blackwell, 2017, 2047-9980

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30201 Cardiac and Cardiovascular systems

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 4.450

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1161/JAHA.116.004332

UT WoS

000393593300009

Keywords in English

acute coronary syndrome; guideline; secondary prevention; statin therapy

Abstract

V originále

Background- High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. Methods and Results- The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as >= 40 mg atorvastatin, >= 20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n = 12 446), 11 850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14 days), but only 5212 (41.9%) were on a high-potency statin. Selected patient factors associated with nonuse of high-potency statins included age >= 75 years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), renal dysfunction (odds ratio 1.17, 95% CI 1.03-1.32), and heart failure during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3 months after baseline, only 49% of patients had low-density lipoprotein cholesterol < 70 mg/dL. Among the 5490 patients (59%) who were not on a high-potency statin at 3 months, lower low-density lipoprotein cholesterol was a predictor of nonuse of a high-potency statin after a median of 2.3 years (odds ratio 1.15 for 10 mg/dL decrease, 95% CI 1.11-1.19). Conclusion- Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with highpotency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events.

Citovat

EISEN, A., C.P. CANNON, E. BRAUNWALD, D.L. STEEN, J. ZHOU, E.L. GOODRICH, K. IM, A.J. DALBY, Jindřich ŠPINAR, S. DAGA, M.A. LUKAS and M.L. O´DONOGHUE. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. Journal of the American Heart Association. Hoboken: Wiley-Blackwell, 2017, vol. 6, No 1, p. 1-9. ISSN 2047-9980. Available from: https://dx.doi.org/10.1161/JAHA.116.004332.

@article{1397227,
   author = {Eisen, A. and Cannon, C.P. and Braunwald, E. and Steen, D.L. and Zhou, J. and Goodrich, E.L. and Im, K. and Dalby, A.J. and Špinar, Jindřich and Daga, S. and Lukas, M.A. and O´Donoghue, M.L.},
   article_location = {Hoboken},
   article_number = {1},
   doi = {http://dx.doi.org/10.1161/JAHA.116.004332},
   keywords = {acute coronary syndrome; guideline; secondary prevention; statin therapy},
   language = {eng},
   issn = {2047-9980},
   journal = {Journal of the American Heart Association},
   title = {Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial},
   url = {http://dx.doi.org/10.1161/JAHA.116.004332},
   volume = {6},
   year = {2017}
}

TY  - JOUR
ID  - 1397227
AU  - Eisen, A. - Cannon, C.P. - Braunwald, E. - Steen, D.L. - Zhou, J. - Goodrich, E.L. - Im, K. - Dalby, A.J. - Špinar, Jindřich - Daga, S. - Lukas, M.A. - O´Donoghue, M.L.
PY  - 2017
TI  - Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial
JF  - Journal of the American Heart Association
VL  - 6
IS  - 1
SP  - 1-9
EP  - 1-9
PB  - Wiley-Blackwell
SN  - 20479980
KW  - acute coronary syndrome
KW  - guideline
KW  - secondary prevention
KW  - statin therapy
UR  - http://dx.doi.org/10.1161/JAHA.116.004332
L2  - http://dx.doi.org/10.1161/JAHA.116.004332
N2  - Background- High-potency statins reduce cardiovascular events after acute coronary syndromes but remain underused in clinical practice. We examined predictors of nonuse of high-potency statins after acute coronary syndromes. Methods and Results- The Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial enrolled patients after an acute coronary syndrome in 36 countries between 2009 and 2011. Statin use was strongly encouraged throughout the trial, and statin potency was at the discretion of the treating physician. A high-potency statin was defined as >= 40 mg atorvastatin, >= 20 mg rosuvastatin, or 80 mg simvastatin daily. Predictors of nonuse of high-potency statins were examined using logistic regression. Of the patients included (n = 12 446), 11 850 (95.2%) were treated with a statin at baseline after acute coronary syndrome (median 14 days), but only 5212 (41.9%) were on a high-potency statin. Selected patient factors associated with nonuse of high-potency statins included age >= 75 years (odds ratio 1.39, 95% CI 1.24-1.56), female sex (odds ratio 1.11, 95% CI 1.02-1.22), renal dysfunction (odds ratio 1.17, 95% CI 1.03-1.32), and heart failure during hospital admission (odds ratio 1.43, 95% CI 1.27-1.62). At 3 months after baseline, only 49% of patients had low-density lipoprotein cholesterol < 70 mg/dL. Among the 5490 patients (59%) who were not on a high-potency statin at 3 months, lower low-density lipoprotein cholesterol was a predictor of nonuse of a high-potency statin after a median of 2.3 years (odds ratio 1.15 for 10 mg/dL decrease, 95% CI 1.11-1.19). Conclusion- Despite the widespread use of statins after acute coronary syndromes, most patients are not treated with highpotency statins early and late after the event, including patients at the highest risk of recurrent cardiovascular events.
ER  -

EISEN, A., C.P. CANNON, E. BRAUNWALD, D.L. STEEN, J. ZHOU, E.L. GOODRICH, K. IM, A.J. DALBY, Jindřich ŠPINAR, S. DAGA, M.A. LUKAS and M.L. O´DONOGHUE. Predictors of Nonuse of a High-Potency Statin After an Acute Coronary Syndrome: Insights From the Stabilization of Plaques Using Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) Trial. \textit{Journal of the American Heart Association}. Hoboken: Wiley-Blackwell, 2017, vol.~6, No~1, p.~1-9. ISSN~2047-9980. Available from: https://dx.doi.org/10.1161/JAHA.116.004332.

Detailed Information on Publication Record